Table 1 Clinicopathologic features of the study population.

Characteristic		N (%) (total N = 23)
Mean age, years (range)		46.8 (34–71)
Primary tumor stage^a	1	4 (17.4)
	2	13 (56.5)
	3	4 (17.4)
	4	2 (8.7)
Primary tumor subtype	HR^b-positive, HER2^c-negative	16 (69.6)
	HER2-positive	2 (8.7)
	HR-negative, HER2-negative	5 (21.7)
Primary tumor operation	Yes	22 (95.7)
Primary tumor operation	No	1 (4.3)
Initial treatment—chemotherapy	Neoadjuvant	6 (26.1)
	Adjuvant	8 (34.8)
	Palliative	2 (8.7)
	None	6 (26.1)
Initial treatment—radiotherapy	Yes	16 (69.6)
	No	6 (26.1)
	Not applicable	1 (4.3)
Initial treatment—endocrine therapy	Yes	17 (73.9)
Initial treatment—endocrine therapy	No	6 (26.1)
Disease-free interval	≤ 5 years	13 (56.5)
	> 5, ≤ 10 years	6 (26.1)
	> 10 years	2 (8.7)
	De novo metastatic	2 (8.7)
Recurrence site at enrollment	Local recurrence only	2^d (8.7)
	Regional ± local recurrence	5 (21.7)
	Distant metastasis	16^d (69.6)
	Visceral	14 (60.9)
	Non-visceral	2 (8.7)

^aCancer staging done according to the AJCC 7th edition.
^bHormone receptor.
^cHuman epidermal growth factor receptor 2.
^dIncluding one case that progressed and metastasized to the pleura during neoadjuvant chemotherapy.

Quick links

Search